ClinicalTrials.gg
CompletedNCT01494987Updated Nov 18, 2014Results posted

Ranolazine When Added to Glimepiride in Subjects With Type 2 Diabetes Mellitus

A Phase 3 interventional study of Ranolazine and Placebo in Type 2 Diabetes Mellitus, sponsored by Gilead Sciences. Completed at 140 sites in 12 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2014-11-18.

Sponsored by Gilead Sciences · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
431
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies testing ranolazine in Diabetes Mellitus, Type 2 — none open to participants now, none under way, none of them phase 3. Ranolazine · Diabetes Mellitus, Type 2.

Enrollment
4th of 11
431 · median 47
Started
2012
with 3 others
Phase 3
4 of 11
none open now
Registered
5th of 11
by date
Lead sponsor
9 of 11
Gilead Sciences

Among the 11 studies testing ranolazine in Diabetes Mellitus, Type 2, this one is the 4th largest by enrollment, is one of 4 that started in 2012, is one of 4 in phase 3, and was the 5th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

None of the 11 studies testing ranolazine in Diabetes Mellitus, Type 2 is open now. The open studies under Diabetes Mellitus, Type 2, anywhere →

About ranolazine

Ranolazine: first FDA approval 2006 (RANEXA), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 11 studies testing ranolazine in Diabetes Mellitus, Type 2 as a file.
02

Study summary

This is a randomized, double-blind, placebo-controlled, parallel-group, multi-center study to determine the effect of ranolazine when added to glimepiride on glycemic control in adults with type 2 diabetes mellitus (T2DM) who are inadequately controlled despite current treatment with stable sulfonylurea or metformin therapy in addition to diet and exercise.

03

Conditions studied

  • Type 2 Diabetes Mellitus

Keywords

  • Type 2 Diabetes Mellitus
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Written
  • Males and females, 18 to 75 years old, inclusive
  • Documented history of T2DM
  • Receiving one of the following sulfonylurea or metformin therapies in addition to diet and exercise for at least 90 days prior to Screening:

    1. glimepiride at a daily dose of ≥ 2 mg and ≤ 4 mg
    2. glipizide, glyburide, or glibenclamide (or equivalent) at a daily dose of ≥ 7.5 mg
    3. gliclazide at a daily dose of > 160 mg (or ≥ 60 mg for the modified release [MR] formulation)
    4. metformin at a daily dose of ≥ 1500 mg
  • (BMI) 25 kg/m2 to 45 kg/m2, inclusive, at Screening
  • 7% to 10%, inclusive, at Screening and the end of the Qualifying Period (Day 14)
  • Fasting Serum C-peptide ≥ 0.8 ng/mL at Screening
  • Fasting serum glucose (FSG) ≥ 130 mg/dL (7.2 mmol/L) and ≤ 240 mg/dL (13.3 mmol/L) at Screening and at the end of the Qualifying Period (Day 14): A one-time central laboratory re-test of FSG is allowed in subjects with an initial central laboratory FSG ≥ 120 mg/dL (6.7 mmol/L) and \< 130 mg/dL (7.2 mmol/L) who are otherwise eligible as determined by the investigator.
  • Able and willing to comply with all study procedures during the course of the study
  • Females of must have a negative serum pregnancy test at Screening and must agree to use highly effective methods from Screening throughout the duration of the Treatment Period and for 14 days following the last dose of study drug.
  • At least 80% compliant in dosing during the Qualifying Period

Exclusion criteria

Exclusion Criteria:

  • History of or current diagnosis of type 1 diabetes mellitus
  • History of diabetic ketoacidosis, ketosis-prone diabetes, or hyperosmolar hyperglycemic coma
  • History of a severe episode of hypoglycemia (≥ 1 episode within 3 months prior to Screening or ≥ 2 episodes within 6 months prior to Screening), defined as hypoglycemia requiring 3rd party assistance to actively administer carbohydrate, glucagon, or other resuscitative actions due to severe impairment in consciousness or behavior
  • complications of diabetes that in the judgment of the investigator would make the subject unsuitable to participate in this study
  • History of any clinically significant cardiovascular (CV) or cerebrovascular event (eg, myocardial infarction [MI], acute coronary syndrome [ACS], recent revascularization [including coronary artery bypass graft procedures or percutaneous coronary intervention], , or ischemic stroke) ≤ 3 months prior to Screening
  • Inadequately controlled or unstable hypertension as defined by a systolic blood pressure (SBP) > 160 mmHg or diastolic blood pressure (DBP) > 100 mmHg at Screening and at Randomization
  • Prolonged corrected for heart rate (QTc) interval > 500 msec by (ECG) at Screening, a personal or family history of QTc prolongation, congenital long QT syndrome, or subjects who are receiving drugs that prolong the QTc interval, such as Class Ia or Class III antiarrhythmic agents, erythromycin, and certain antipsychotics (eg, ziprasidone)
  • History of bariatric surgery at any time in the past or or any other surgery \< 2 months before Screening; or planning to undergo surgery during the study. Subjects with a planned minor surgery may be enrolled upon approval by the medical monitor.
  • Any other hospitalization in the 14 days prior to Screening or planned hospitalization at any time during the study
  • Significant weight change (± 5%) \< 2 months prior to Screening or enrollment in a weight-loss program other than a maintenance phase at Screening.
  • Severe renal impairment, defined as an estimated (eGFR) by the Modification of Diet in Renal Disease (MDRD) equation \< 30 mL/min/1.73 m2 at Screening or undergoing any type of dialysis at Screening or planning to undergo any type of dialysis during the course of the study
  • History of liver cirrhosis ( Class A, B or C)
  • Active liver disease and/or significant abnormal liver function defined as (AST) > 3 x (ULN) and/or alanine aminotransferase (ALT) > 3 x ULN and/or serum total > 2.0 mg/dL
  • History of cancer (except nonmelanomic skin cancers or cervical in situ) within 5 years prior to Screening
  • History of alcohol or other drug abuse \< 12 months prior to Screening
  • Any other clinically significant existing medical or psychiatric condition, including clinically significant laboratory abnormalities, or one requiring further evaluation that in the opinion of the investigator could interfere with conduct of the study or interpretation of the data
  • Use of antihyperglycemic agents other than sulfonylurea agents or metformin, including but not limited to dipeptidyl peptidase-4 inhibitors (eg, saxagliptin and sitagliptin), glucagon-like peptide-mimetics (eg, exenatide), or insulin \< 3 months prior to Screening; use of thiazolidinediones (TZDs) (eg, rosiglitazone or pioglitazone) \< 24 weeks prior to Screening
  • Previous history of intolerance of glimepiride (as a single-agent therapy)
  • Prior treatment with open-label ranolazine, or known or intolerance to ranolazine or any of its
  • Treatment with strong or moderate cytochrome P (CYP)3A inhibitors or P-glycoprotein (P-gp) inhibitors within 14 days prior to randomization
  • Treatment with inducers or P-gp inducers within 14 days prior to randomization
  • Treatment with CYP3A4 substrates with a narrow therapeutic range (eg, cyclosporine, tacrolimus, or sirolimus) within 14 days prior to Randomization
  • Treatment with simvastatin at a dose of > 20 mg daily or lovastatin at a dose of > 40 mg daily within 14 days prior to Randomization
  • Weight loss medication or anti-obesity medication (prescription or non-prescription) \< 3 months prior to Screening
  • Treatment with niacin > 200 mg daily; if receiving ≤ 200 mg daily, should be on stable doses for ≥ 3 months prior to Screening
  • Expected or current treatment with systemic (oral or injectable) for > 14 days from Screening through the end of the Treatment Period. Topical or inhaled corticosteroid formulations are permitted at any time during the study.
  • If receiving thyroid replacement therapy, should be on stable doses for at least 6 weeks prior to randomization
  • \< 12 g/dL for males or \< 11 g/dL for females at Screening
  • Participation in another clinical study involving an drug or device \< 30 days prior to Screening; participation in another clinical study involving an oral antihyperglycemic agent (OHA) \< 90 days prior to Screening
  • Donation of blood \< 2 months prior to Screening or plans to donate blood while participating in the study
  • Females who are pregnant or are breastfeeding
  • Other condition(s) that, in the opinion of the investigator, would compromise the safety of the individual, prevent compliance with the study protocol (including the ability to comply with Mixed Meal Tolerance Test [MMTT]), or compromise the quality of the clinical study
Terms in these criteria, in plain language(20)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
431 participants (actual)

Study arms

  • Experimental
    Ranolazine+glimepiride

    Glimepiride stabilization period (up to 8 weeks): participants not on stable glimepiride will receive glimepiride 2 mg once daily, and if tolerated the dose will be increased on Day 8 (+ 2 days) to 4 mg once daily. Qualifying period: participants will receive placebo to match ranolazine twice daily in addition to glimepiride for 14 days (+ 2 days) and if ≥ 80% compliant and meeting eligibility criteria will continue to the treatment period. Treatment period: participants will be randomized to receive ranolazine 500 mg twice daily plus glimepiride 4 mg once daily on Days 1 through 7, followed by ranolazine 1000 mg twice daily plus glimepiride 4 mg once daily from Day 8 (or by Day 16 if not well tolerated) through Week 24. Participants will be required to maintain their diet and exercise regimen.

    Drug: Ranolazine · Drug: Glimepiride · Behavioral: Diet · Behavioral: Exercise

  • Placebo comparator
    Placebo+glimepiride

    Glimepiride stabilization period (up to 8 weeks): participants not on stable glimepiride will receive glimepiride 2 mg once daily, and if tolerated the dose will be increased on Day 8 (+ 2 days) to 4 mg once daily. Qualifying period: participants will receive placebo to match ranolazine twice daily in addition to glimepiride for 14 days (+ 2 days) and if ≥ 80% compliant and meeting eligibility criteria will continue to the treatment period. Treatment period: participants will be randomized to receive placebo to match ranolazine plus glimepiride 4 mg once daily for 24 weeks. Participants will be required to maintain their diet and exercise regimen.

    Drug: Placebo · Drug: Glimepiride · Behavioral: Diet · Behavioral: Exercise

Interventions

  • Ranolazine tablet(s) administered orally

    Also known as: Ranexa®

  • DrugPlacebo

    Placebo to match ranolazine for the duration of the study

  • Glimepiride tablets (2 mg or 4 mg) administered orally once daily with the morning dose of study drug or placebo. The target dosing regimen for glimepiride is 4 mg once daily.

  • BehavioralDiet

    Participants are instructed to continue the diet regimen prescribed by their physician.

  • BehavioralExercise

    Participants are instructed to continue the exercise regimen prescribed by their physician.

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 24

    The average (mean) change from baseline in HbA1c at Week 24 was analyzed.

    Time frame: Baseline; Week 24

Secondary outcomes

  1. Change From Baseline in Incremental Change of 2-hour Postprandial Serum Glucose at Week 24

    The average (mean) change from baseline in incremental change of 2-hour postprandial serum glucose at Week 24 was analyzed. Mixed Meal Tolerance Test (MMTT) Full Analysis Set: randomized participants who received at least one dose of study treatment with a baseline and at least one postbaseline measurement of serum glucose at T=120 minutes during the MMTT, administered under fasting conditions, excluding participants with major eligibility protocol violations, analyzed based on the randomized treatment regardless of actual treatment received.

    Time frame: Baseline; Week 24

  2. Change From Baseline in Fasting Serum Glucose at Week 24

    The average (mean) change from baseline in fasting serum glucose at Week 24 was analyzed.

    Time frame: Baseline; Week 24

  3. Change From Baseline in 2-hour Postprandial Serum Glucose at Week 24

    The average (mean) change from baseline in 2-hour postprandial serum glucose at Week 24 was analyzed.

    Time frame: Baseline; Week 24

07

Results

Posted Sep 1, 2014

Participant flow

Participants were enrolled (during the Qualifying Period) at a total of 103 study sites in Asia, Europe, South Africa, and the United States. The first participant was screened on 12 January 2012. The last participant observation occurred on 28 August 2013.

Participant flow — Overall Study
MilestonePlacebo+GlimepirideRanolazine+Glimepiride
Started216215
Completed188187
Not completed2828
Withdrew: Adverse event65
Withdrew: Hyperglycemia64
Withdrew: Investigator's discretion12
Withdrew: Lost to follow-up11
Withdrew: Protocol violation33
Withdrew: Subject non-compliance910
Withdrew: Subject withdrew consent23

Outcome measures

PrimaryChange From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 24

The average (mean) change from baseline in HbA1c at Week 24 was analyzed.

Time frame:
Baseline; Week 24
Reported as:
Mean · percent of HbA1c in blood
Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 24
percent of HbA1c in bloodPlacebo+GlimepirideRanolazine+Glimepiride
HbA1c at Week 248.08 ± 1.0707.58 ± 1.089
Change from baseline in HbA1c at Week 240.03 ± 0.949-0.47 ± 0.971
Statistical analysis
  • Placebo+Glimepiride vs Ranolazine+Glimepiride · Mixed Effects Model Analysis · p = <0.001 (P-value is from a mixed-effect model including terms for baseline HbA1c value, prior antihyperglycemia therapy, treatment group, visit week, and treatment by visit week interaction. Unstructured covariance matrix was used.) · Difference in least squares mean (lsm): -0.51 · 95% CI -0.71 to -0.32The estimation (LSM) is of the placebo-corrected change from baseline.
SecondaryChange From Baseline in Incremental Change of 2-hour Postprandial Serum Glucose at Week 24

The average (mean) change from baseline in incremental change of 2-hour postprandial serum glucose at Week 24 was analyzed. Mixed Meal Tolerance Test (MMTT) Full Analysis Set: randomized participants who received at least one dose of study treatment with a baseline and at least one postbaseline measurement of serum glucose at T=120 minutes during the MMTT, administered under fasting conditions, excluding participants with major eligibility protocol violations, analyzed based on the randomized treatment regardless of actual treatment received.

Time frame:
Baseline; Week 24
Reported as:
Mean · mg/dL
Change From Baseline in Incremental Change of 2-hour Postprandial Serum Glucose at Week 24
mg/dLPlacebo+GlimepirideRanolazine+Glimepiride
Change From Baseline in Incremental Change of 2-hour Postprandial Serum Glucose at Week 24-2 ± 42.61 ± 44.7
SecondaryChange From Baseline in Fasting Serum Glucose at Week 24

The average (mean) change from baseline in fasting serum glucose at Week 24 was analyzed.

Time frame:
Baseline; Week 24
Reported as:
Mean · mg/dL
Change From Baseline in Fasting Serum Glucose at Week 24
mg/dLPlacebo+GlimepirideRanolazine+Glimepiride
Change From Baseline in Fasting Serum Glucose at Week 248 ± 40.72 ± 45.3
SecondaryChange From Baseline in 2-hour Postprandial Serum Glucose at Week 24

The average (mean) change from baseline in 2-hour postprandial serum glucose at Week 24 was analyzed.

Time frame:
Baseline; Week 24
Reported as:
Mean · mg/dL
Change From Baseline in 2-hour Postprandial Serum Glucose at Week 24
mg/dLPlacebo+GlimepirideRanolazine+Glimepiride
Change From Baseline in 2-hour Postprandial Serum Glucose at Week 244 ± 58.01 ± 59.6

Adverse events

Collected over Up to 24 weeks plus 30 days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo+Glimepiride—4/216 (1.9%)46/216 (21.3%)
Ranolazine+Glimepiride—4/215 (1.9%)42/215 (19.5%)
Most frequent serious events
Most frequent serious events
EventPlacebo+GlimepirideRanolazine+Glimepiride
Myocardial ischaemiaCardiac disorders0/2161/215
Eye haemorrhageEye disorders0/2161/215
Retinal vein thrombosisEye disorders0/2161/215
Back painMusculoskeletal and connective tissue disorders0/2161/215
Breast cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/2161/215
Acute myocardial infarctionCardiac disorders1/2160/215
Ventricular extrasystolesCardiac disorders1/2160/215
Ischaemic strokeNervous system disorders1/2160/215
Pulmonary embolismRespiratory, thoracic and mediastinal disorders1/2160/215
Most frequent other events
Most frequent other events
EventPlacebo+GlimepirideRanolazine+Glimepiride
HyperglycemiaMetabolism and nutrition disorders32/21621/215
HypoglycaemiaMetabolism and nutrition disorders10/21613/215
NauseaGastrointestinal disorders7/21611/215

Baseline characteristics

Baseline characteristics are reported for the Safety Analysis Set following randomization. The Safety Analysis Set includes randomized participants who received at least one dose of study treatment.

Age, Continuous
Age, Continuous(years)Placebo+GlimepirideRanolazine+GlimepirideTotal
Mean59 ± 8.659 ± 8.859 ± 8.7
Sex: Female, Male
Sex: Female, Male(Participants)Placebo+GlimepirideRanolazine+GlimepirideTotal
Female123120243
Male9395188
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Placebo+GlimepirideRanolazine+GlimepirideTotal
Hispanic or Latino323264
Not Hispanic or Latino181182363
Unknown or Not Reported314
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Placebo+GlimepirideRanolazine+GlimepirideTotal
American Indian or Alaska Native101
Asian437
Black or African American10313
Native Hawaiian or Other Pacific Islander101
White198204402
Other257
Region of Enrollment
Region of Enrollment(participants)Placebo+GlimepirideRanolazine+GlimepirideTotal
Serbia404
United States6160121
Czech Republic101
Hungary4610
Slovakia123
Poland549
Ukraine262753
Romania11920
South Africa437
Russian Federation99104203
Body Mass Index
Body Mass Index(kg/m^2)Placebo+GlimepirideRanolazine+GlimepirideTotal
Mean32.8 ± 4.3532.2 ± 3.8832.5 ± 4.13
Glycosylated hemoglobin (HbA1c)
Glycosylated hemoglobin (HbA1c)(percent HbA1c in blood)Placebo+GlimepirideRanolazine+GlimepirideTotal
Mean8.10 ± 0.7468.07 ± 0.7768.08 ± 0.760
Fasting Serum Glucose
Fasting Serum Glucose(mg/dL)Placebo+GlimepirideRanolazine+GlimepirideTotal
Mean177.2 ± 34.27177.4 ± 37.03177.3 ± 35.63

2 further baseline measures are reported on the registry.

08

Study locations

140 sites
  • Clinical Research Advantage/Desert Clinical Research, LLC
    Mesa, Arizona 85213, United States
  • Desert Sun Clinical Research, LLC
    Tucson, Arizona 85710, United States
  • Eclipse Clinical Research
    Tucson, Arizona 85745, United States
  • Paul W. Davis, MD, PA
    Pine Bluff, Arkansas 71603, United States
  • Southland Clinical Research Center, Inc.
    Fountain Valley, California 92708, United States
  • Valley Research
    Fresno, California 93720-2992, United States
  • Del Rosario Medical Clinic, Inc.
    Huntington Park, California 90255, United States
  • Scripps Whittier Diabetes Institute
    La Jolla, California 92037, United States
  • National Research Institute
    Los Angeles, California 90057, United States
  • Spectrum Clinical Research Institute, Inc
    Moreno Valley, California 92553, United States
  • Sacramento Heart and Vascular Medical Associates
    Sacramento, California 95825, United States
  • Infosphere Clinical Research
    West Hills, California 91307, United States
  • PAB Clinical Research
    Brandon, Florida 33511, United States
  • Florida Research Network, LLC
    Gainesville, Florida 32605-4253, United States
  • NewPhase Clinical Trials, Inc.
    Miami Beach, Florida 33140, United States
  • Suncoast Clinical Research
    New Port Richey, Florida 34652, United States
  • Regenerate Clinical Trials
    South Miami, Florida 33143, United States
  • Comprehensive Clinical Development, Inc.
    St. Petersburg, Florida 33716, United States
  • Clinical Research of Central Florida
    Winter Haven, Florida 33880, United States
  • Synergy Therapeutic Partners
    Atlanta, Georgia 30127, United States
  • CTL Research
    Eagle, Idaho 83616, United States
  • Cedar-Crosse Research Center
    Chicago, Illinois 60607, United States
  • LaPorte County Institute for Clinical Research
    Michigan City, Indiana 46360, United States
  • L-MARC Research Center
    Louisville, Kentucky 40213, United States
  • Horizon Research Group of Opelousas
    Eunice, Louisiana 70535, United States
  • MD Medical Research
    Oxon Hill, Maryland 20745, United States
  • IRC Clinics, Inc
    Towson, Maryland 21204, United States
  • Endeavor Medical Research, PLC
    Alpena, Michigan 49707, United States
  • Associated Internal Medicine Specialists, P.C.
    Battle Creek, Michigan 49015, United States
  • Albuquerque Clinical Trials
    Albuquerque, New Mexico 87102, United States
  • PMG Research of Charlotte
    Charlotte, North Carolina 28209, United States
  • PharmQuest
    Greensboro, North Carolina 27408, United States
  • Clinical Inquest Center, Ltd.
    Beavercreek, Ohio 45431, United States
  • Infinity Research Group, LLC
    Oklahoma City, Oklahoma 73103, United States
  • Southeastern Research Associates, Inc.
    Taylors, South Carolina 29687, United States
  • HCCA Clinical Research Solution
    Franklin, Tennessee 37067, United States
  • Holston Medical Group
    Kingsport, Tennessee 37660-3256, United States
  • New Phase Research & Development
    Knoxville, Tennessee 37923, United States
  • The University of Texas Southwestern Medical Center at Dallas
    Dallas, Texas 75390, United States
  • Excel Clinical Research, LLC
    Houston, Texas 77081, United States
  • Texas Center for Drug Development, Inc.
    Houston, Texas 77081, United States
  • Humble Cardiology Associates
    Humble, Texas 77338, United States
  • Cetero Research
    San Antonio, Texas 78229, United States
  • Cetero Research
    San Antonio, Texas 78237, United States
  • Highland Clinical Research
    Salt Lake City, Utah 84124, United States
  • Jean Brown Research
    Salt Lake City, Utah 84124, United States
  • Interni oddeleni
    Havirov, Moravskoslezsky kraj 736 01, Czech Republic
  • Drug Research Center
    Balatonfüred, 8230, Hungary
  • Synexus Hungary Ltd
    Budapest, 1036, Hungary
  • Markhot Ferenc Hospital
    Eger, 3300, Hungary
  • Kanizsai Dorottya Hospital
    Nagykanizsa, 8800, Hungary
  • Borbanya Praxis Kft., Outpatient Clinic
    Nyíregyháza, 4400, Hungary
  • Medifarma 98
    Nyíregyháza, 4400, Hungary
  • Hospital Universiti Sains Malaysia
    Kubang Kerian, Kelantan 16150, Malaysia
  • NZOZ Centrum Badan Klinicznych
    Wroclaw, Dolnoslaskie 50-349, Poland
  • Centrum Terapii Wspolczesnej J.M. Jasnorzewska Sp. Komandytowo - Akcyjna
    Lodz, Lodzkie 90-242, Poland
  • NZOZ Centrum Medyczne Szpital Sw. Rodziny
    Lodz, Lodzkie 90-302, Poland
  • NZOZ Polimedica
    Zgierz, Lodzkie 95-100, Poland
  • Centrum Badan Klinicznych PI-House Sp. z o.o.
    Gdansk, Pomorskie 80-546, Poland
  • LANDA - Specjalistyczne Gabinety Lekarskie
    Krakow, 30-015, Poland
  • SPZOZ Uniwersytecki Szpital Kliniczny Nr 1 im. Norberta Barlickiego Uniwersytetu Medycznego w Łodzi, Oddział Kliniczny Diabetologii
    Lodz, 90-153, Poland
  • NZOZ Centrum Badan Klinicznych Oswiecim
    Oswięcim, 32-600, Poland
  • Spital Clinic Judetean de Urgenta Oradea Stationarul 1
    Oradea, Jud Bihor 410169, Romania
  • Consultmed SRL
    Iasi, Jud. Iasi 700547, Romania
  • CMI Morosanu V. Magdalena
    Galati, Judetul Galati 800371, Romania
  • Centru Medical Dr. Negrisanu
    Timisoara, Judical Timis 300456, Romania
  • Tehnomed Trading Srl
    Bucharest, 020354, Romania
  • O.D. Medica Srl
    Bucharest, 020725, Romania
  • Institutul de Diabet, Nutritie si Boli Metabolice "Dr. N. C. Paulescu"
    Bucuresti, 020042, Romania
  • Institutul National De Diabet, Nutritie Si Boli Metabolice "Prof. Dr. N.C. Paulescu"
    Bucuresti, 020475, Romania
  • CMI Mateescu S. Ana-Maria
    Constanta, 900675, Romania
  • Spitalul Clinic Judetean de Urgenta "Sf. Apostol Andrei" Galati
    Galati, 800578, Romania
  • Diabmed Dr. Popescu Alexandrina SRL
    Ploiesti, 100163, Romania
  • 3rd Central Military Clinical Hospital named after A.A.Vishnevskogo
    Arkhangelskoe, 143420, Russian Federation
  • GOU VPO "Chita State Medical Academy" of Minzdravsocrazvitie RF
    Chita, 672090, Russian Federation
  • "Clinic of New Medical Technology" Company Limited
    Dzerzhinskiy, 140091, Russian Federation
  • The Urals State Medical Academy
    Ekaterinburg, 620102, Russian Federation
  • Kemerovo Regional Clinical Hospital
    Kemerovo, 650066, Russian Federation
  • "Krasnoyarsk State Medical University n.a. Prof. V.F. Voyno-Yasenetsky
    Krasnoyarsk, 660062, Russian Federation
  • State Healthcare Institution of Moscow "Cardiologival Dispensary #2 of Management Department of South Administrative District"
    Moscow, 117556, Russian Federation
  • Central Clinical Hospital of Russian Academy of Sciences
    Moscow, 117593, Russian Federation
  • Medical Sanitary Unit of Minestry of Internal Affairs of Russia in Moscow
    Moscow, 127299, Russian Federation
  • City Clinical Hospital # 13 of Avtozavodsky District of Nizhniy Novgorod
    Nizhniy Novgorod, 603018, Russian Federation
  • Novosibirsk State Medical University
    Novosibirsk, 630087, Russian Federation
  • Scientific Research Institute of Physiology of Siberian Department RAMS
    Novosibirsk, 630117, Russian Federation
  • City Hospital # 38 named after N A Semashko
    Pushkin, 196601, Russian Federation
  • Rostov State Medical University
    Rostov-on-Don, 344022, Russian Federation
  • Ryazan State Medical University
    Ryazan, 390005, Russian Federation
  • Center "Diabetes", LLC
    Samara, 443067, Russian Federation
  • Smolensk State Medical Academy, Sanatorium-Preventorium
    Smolensk, 214019, Russian Federation
  • Medinet, LLC
    St. Petersburg, 190000, Russian Federation
  • North-Western State Medical Unversity n.a. I.I.Mechnikov
    St. Petersburg, 191015, Russian Federation
  • Saint-Petersburg City Outpatient Clinic#37
    St. Petersburg, 191119, Russian Federation
  • Military Medical Academy named after S.M. Kirov
    St. Petersburg, 191124, Russian Federation
  • Saint-Petersburg state budgetary healthcare institution "City Polyclinic #109"
    St. Petersburg, 192283, Russian Federation
  • Alexanders City Hospital
    St. Petersburg, 193312, Russian Federation
  • Clinical Hospital #122 n.a. Sokolov of FMBA
    St. Petersburg, 194291, Russian Federation
  • ANO "Medical Centre "XXI century"
    St. Petersburg, 194354, Russian Federation
  • St. Elizabeth City Hospital
    St. Petersburg, 195257, Russian Federation
  • Krestovsky Island Medical Institute, LLC
    St. Petersburg, 197042, Russian Federation

Showing the first 100 of 140 sites across 12 countries. Choose a country and city above to see the rest.

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2012, a primary completion of Aug 2013 and a completion of Aug 2013. It does not say whether these dates are actual or estimated.

Results were first posted in Sep 2014, 1 year 1 month after primary completion. A results delay was requested in Dec 2013.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 15, 2011
First posted
Dec 19, 2011
Start
Jan 2012
Primary completionActual
Aug 2013
CompletionActual
Aug 2013
Results delay requested
Dec 12, 2013
Results first posted
Sep 1, 2014
Last update
Nov 18, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 18, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01494987
Lead sponsor
Gilead Sciences
Responsible party
Sponsor
First posted
Dec 19, 2011
Start date
Jan 2012
Primary completion
Aug 2013
Completion
Aug 2013
Results posted
Sep 1, 2014
Last update
Nov 18, 2014

Study contacts

Patrick Yue, MD
study director · Gilead Sciences

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ranolazine

Start the discussion